| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Cancer Biology and Genetics, Cancer Research Institute, and Departments of Biochemistry and of Pathology and Molecular Medicine, Queen’s University, Kingston, Ontario, Canada
Multidrug Resistance Proteins (MRPs), together with the cystic fibrosis conductance regulator (CFTR/ABCC7) and the sulfonylurea receptors (SUR1/ABCC8 and SUR2/ABCC9) comprise the 13 members of the human "C" branch of the ATP binding cassette (ABC) superfamily. All C branch proteins share conserved structural features in their nucleotide binding domains (NBDs) that distinguish them from other ABC proteins. The MRPs can be further divided into two subfamilies "long" (MRP1, -2, -3, -6, and -7) and "short" (MRP4, -5, -8, -9, and -10). The short MRPs have a typical ABC transporter structure with two polytropic membrane spanning domains (MSDs) and two NBDs, while the long MRPs have an additional NH2-terminal MSD. In vitro, the MRPs can collectively confer resistance to natural product drugs and their conjugated metabolites, platinum compounds, folate antimetabolites, nucleoside and nucleotide analogs, arsenical and antimonial oxyanions, peptide-based agents, and, under certain circumstances, alkylating agents. The MRPs are also primary active transporters of other structurally diverse compounds, including glutathione, glucuronide, and sulfate conjugates of a large number of xeno- and endobiotics. In vivo, several MRPs are major contributors to the distribution and elimination of a wide range of both anticancer and non-anticancer drugs and metabolites. In this review, we describe what is known of the structure of the MRPs and the mechanisms by which they recognize and transport their diverse substrates. We also summarize knowledge of their possible physiological functions and evidence that they may be involved in the clinical drug resistance of various forms of cancer.
This article has been cited by other articles:
|
|
 |
|
  T.-Y. Chen and T.-C. Hwang CLC-0 and CFTR: Chloride Channels Evolved From Transporters Physiol Rev, April 1, 2008; 88(2): 351 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rius, J. Hummel-Eisenbeiss, and D. Keppler ATP-Dependent Transport of Leukotrienes B4 and C4 by the Multidrug Resistance Protein ABCC4 (MRP4) J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 86 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Erives, S. S. Lau, and T. J. Monks Accumulation of Neurotoxic Thioether Metabolites of 3,4-({+/-})-Methylenedioxymethamphetamine in Rat Brain J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 284 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. P. Lin, Y.-L. Zhu, D. R. Johnson, K. P. Rice, T. Nottoli, B. C. Hains, J. McGrath, S. G. Waxman, and A. C. Sartorelli Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response Mol. Pharmacol., January 1, 2008; 73(1): 243 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-P. Wu, S. Shukla, A. M. Calcagno, M. D. Hall, M. M. Gottesman, and S. V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol. Cancer Ther., December 1, 2007; 6(12): 3287 - 3296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Currie, B. King, A. L. Lawrenson, L. K. Schroeder, A. M. Kershner, and G. J. Hermann Role of the Caenorhabditis elegans Multidrug Resistance Gene, mrp-4, in Gut Granule Differentiation Genetics, November 1, 2007; 177(3): 1569 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. J. Letourneau, A. J. Slot, R. G. Deeley, and S. P. C. Cole Mutational Analysis of a Highly Conserved Proline Residue in MRP1, MRP2, and MRP3 Reveals a Partially Conserved Function Drug Metab. Dispos., August 1, 2007; 35(8): 1372 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Willoughby and D. M. F. Cooper Organization and Ca2+ Regulation of Adenylyl Cyclases in cAMP Microdomains Physiol Rev, July 1, 2007; 87(3): 965 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Filipits, V. Haddad, K. Schmid, A. Huynh, A. Dunant, F. Andre, E. Brambilla, R. Stahel, J.-P. Pignon, J.-C. Soria, et al. Multidrug Resistance Proteins Do Not Predict Benefit of Adjuvant Chemotherapy in Patients with Completely Resected Non-Small Cell Lung Cancer: International Adjuvant Lung Cancer Trial Biologic Program Clin. Cancer Res., July 1, 2007; 13(13): 3892 - 3898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Leprohon, D. Legare, I. Girard, B. Papadopoulou, and M. Ouellette Modulation of Leishmania ABC Protein Gene Expression through Life Stages and among Drug-Resistant Parasites. Eukaryot. Cell, October 1, 2006; 5(10): 1713 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol Rev, October 1, 2006; 86(4): 1179 - 1236. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
